Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|December 1, 2015

Vetter Receives AEO-F Certificate from EU

Vetter receives AEO-F certificate from the European Union for global movement of goods.

On Dec. 1, 2015 Vetter Pharmaceuticals, a Germany-based contract development and manufacturing organization (CDMO), announced the company had received an Authorized Economic Operator Full (AEO-F) certificate for global movement of goods from the European Union.

According to the European Commission, to qualify for AEO-F certification, a company must demonstrate a good record of compliance with customs requirements, satisfactory system of managing commercial and transport, records which allow appropriate customs controls, proven financial solvency, and appropriate security and safety standards.

The AEO-F is currently accepted by the United States, Japan, European Union Member states, Switzerland, Norway, and China. Ecuador and El Salvador are expected to launch AEO programs by the end of 2015. According to the company, this certification will aid in facilitating the import of drugs, allowing it to transport pharmaceuticals more quickly, and at a lower cost.

The World Custom’s Organization (WCO) says there are currently a total of 12,367 AEO companies in the United States and Canada alone. Outside the North American market, the organization says there are a total of 450 AEO companies. By expanding the AEO programs, the WCO hopes to establish a uniform customs and security standard in the international movement of goods, with the Standards to Secure and Facilitate Global Trade (SAFE) program.

Vetter Pharmaceuticals has facilities in Germany and the United States. The company recently began operating a branch in Singapore, and Tokyo. The company focuses on fill and finish of aseptically prefilled syringe systems, cartridges, and vials; it also has services for the commercial filling and packaging of parenteral drugs.

Source: Vetter Pharmaceuticals


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.